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B. Pitt: Dr. Bourassa, there seem to be some diierences 
between the data that Dr. Ho presented on the mortality rate 
in women as compared with the data in the SOLVD Reeis- 
try. Because women tend to be older, do the mortality rates 
decrease if you adjust he SOLVD Registry data for differ- 
ences in age? 
M. Bourpsse: In the SOLVD Registry data base, women 
were at least 5 years older than men, but after adjustment for 
age, there was still a higher incidence of events in women 
than in men. 
P. I%&-Wilsem How can you explain the very high 
incidence of hypertension i the Framingham Study? In 
recent data from Europe the number of cases of heart failure 
caused by hypertension is much lower than the data from 
Flamblghanl. 
K. Ho: It is difiicuh to attribute specific auses to cases of 
heart failure, especially inpatients with multiple preexisting 
medical conditions. In the Pram&ham Study, the percent- 
age of patients with heart failure who had a history of 
hypertension is approximately 70%. One of the advantages 
of the Framingham Study is that we followed up patients for 
40 years, and hypertension can be diagnosed at anytime 
during this 40-year period. 
B. Pitt: We were impressed by overwhelming prevalence 
of ischemic heart disease in the SOLVD Registry data 
base. 
T. Smith: I was intrigued by that same 8nding. Most of 
us have taken note of the high incidence of hypertension 
in the original publication of the Framingham data by 
McKee et al. (McKee PA, Castegi WP, McNamara PM, 
Kannel WB. The natural history of congestive heart 
failure: the Framingham Study. N Engl J Med 1971;285: 
1441-9, which diiers from the findings in other studies 
of heart failure. In addition, in the McKee report, there 
was a Syear mortality rate of approximately 40% in women 
and approximately 60% in men. Now you are showing 
us data that are significantly worse than the rates in the 
original report. What differences in patient demographics 
could account for that? Or alternatively, what changes in 
practice? 
K* Ho: The data that I showed you were not age adjusted; 
they were overah survival rates. In addition, the data that I
presented today includes the offspring of the oigind 
01993 by the Americat~ C~Uegc of Catiiobgy 
Framingham cohort, a younger group than the population 
included in the 1971 report. 
T. Smith: That should make things better, shouldn’t i ? 
Not worse. 
K. Ho: Yes. However, at the same time the original 
population is growing older and a higher proportion of the 
origiil cohort is dying. 
S. Yusufz The data you presented today indicate aprog- 
nosis that was about wice as poor as that reported in the 
earlier eport from Framingham. In the SOLVD prevention 
trial, patients were followed up until they developed heart 
failure and then were followed up for many years. Even in 
this group with new onset heart failure, the mortality rate is 
only approximately 30% at 2 years, a mortality rate that is 
substantially ower than yours. The only explanation I can 
think of is that patients older than 80 years were not included 
in the SOLVD trial. 
M. Packer: Some of the differences in mortality among 
studies of heart failure may be related to differences in how 
heart failure was defined. The criteria proposed by Dr. Ho 
are appropriate if one is conducting a iarge population-based 
study. In contrast, I believe that the SOLVD Registry 
primarily focused on hospitalized patients. 
Clinicians are heavily iniluenced by measures ofventric- 
ular function. I believe that many physicians ignore the signs 
and symptoms Dr. Ho has used as criteria for the diagnosis 
of heart faihue when the left ventricular ejection fraction is 
normal-even though that might not be appropriate. I won- 
der to what degree the changes you have seen from 1971 to 
the present are influenced by the increasing use of noninva- 
sive tests. For example, is it possible that many patients 
given the diagnosis ofheart failure in the 1970s had diastolic 
dysfunction? Such patients might be excluded by physicians 
participating in epidemiologic surveys catried out in the 
1980s and 1990s. 
K. Ho: The data that I showed used criteria instituted in 
the 1940s. We did not use measures of left ventricular 
systolic function, so the criteria have remained the same for 
40 years. 
W. Celucei: Do you have measurements of ejection 
fraction in a subset of patients? Do you have any way of 
giving us a rough estimate? 
K. Ho: There are some direct and indirect data. We have 




performed echocardiograms during the last several examina- 
tion cycles in the Framingham patients, but we have not 
measured ejection fraction. Marantz et al. (Marantz PM, 
Tobin JN, Wasserthett-Smeller S, et al. The relationship 
between left ventricular systolic function and congestive 
heart failure diagnosed by clinical criteria. Grculation 1988; 
77:607-12) evaluated the ability of clinical criteria to predict 
ejection fraction in patients with congestive h art failure. On 
the basis of their population of patients referred for radio- 
nuclide ventriculograms, they fottnd that he criteria used in 
the Framingham Study were 63% sensitive and 63% specific 
for predicting a left ventricular ejection fraction of ZQIo%. 
